Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

Figure 3

Serum and tissue redox status markers. Serum MDA (a) and TAS (b) and pancreas (c) and heart (d) MDA, for the control ($+/+$) and diabetic (fa/fa) ZDF rats, in the initial and final times (6 weeks of vehicle or 10 mg/kg BW/day sitagliptin treatment). Comparisons between groups ($n=8$ each): a - ZDF (fa/fa) versus ZDF ($+/+$) and b - with sita versus without sita; $P<.05\text{,}$$P<.01$ and $P<.001$ for one, two or three letters, respectively. MDA, malondialdehyde; TAS, total antioxidant status.

(a)

(b)

(c)

(d)